White House Withdraws FDA Nominee Overton as Senate Support Collapses

The White House has withdrawn the nomination of Dr. Heidi Overton for Food and Drug Administration (FDA) commissioner, a day before a scheduled Senate committee vote. Overton, a domestic policy adviser involved in controversial health policies, lacked the necessary Republican support to advance. The FDA remains under acting leadership as Republicans consider alternative candidates, including former Senator Roger Marshall, before Democrats take control of the Senate in January.
Key points
- The White House withdrew Dr. Heidi Overton’s nomination for FDA commissioner on November 17, 2026, ahead of a Senate Health Committee vote.
- Overton faced opposition from Democrats, moderate Republicans, and Make America Healthy Again (MAHA) supporters, with key senators citing concerns over her experience and policy stances.
- The FDA has operated under acting leadership since former Commissioner Marty Makary was removed in May 2026 after clashing with the White House over flavored vapes and abortion pill regulations.
- Republicans are considering former Senator Roger Marshall as a potential replacement nominee, as he is viewed as more confirmable than Overton.
- The withdrawal occurs amid a broader political shift, with Democrats holding a 55-44 Senate majority following the 2026 midterm elections.
Background
The FDA has been without a permanent commissioner since May 2026, when Marty Makary was pushed out after disagreements with the White House over flavored vapes and mifepristone regulations. Kyle Diamantas, a former top food official, has served as acting commissioner but is reportedly eyeing a departure. The current nomination struggle follows a period of intense political pressure on health policies, including debates over unapproved peptides and vaccine regulations, as detailed in earlier coverage.
How outlets are covering it
The Washington Post and The New York Times both reported the withdrawal of Overton’s nomination, citing lack of Republican support. The New York Times noted that Overton would have needed every Republican vote on the Senate health committee to advance, while The Washington Post highlighted opposition from both Democrats and MAHA supporters. Semafor emphasized the time crunch facing Republicans, with only a month and a half left in their majority to confirm nominees, and highlighted the consideration of Roger Marshall as a replacement. The Guardian’s coverage, while focused on the Alaska Senate race, noted the broader Democratic gains in the 2026 midterms, which impact the political landscape for such appointments.
Why it matters
The withdrawal of Overton’s nomination highlights the deep political divisions over health policy and the challenges facing the Trump administration in confirming key officials. The FDA’s leadership vacuum could impact regulatory decisions on critical issues, including drug approvals and public health measures. As Democrats take control of the Senate in January, the ability to confirm nominees will be further constrained, making the current window crucial for the administration.
What to watch
Republicans are expected to finalize a decision on an alternative nominee, with Roger Marshall emerging as a leading candidate. The Senate Health Committee was scheduled to vote on Overton’s nomination on November 18, but the withdrawal may delay further action. The FDA will continue under acting leadership, with Kyle Diamantas potentially departing regardless of the outcome. The political landscape will shift significantly in January when Democrats take control of the Senate, limiting the administration’s ability to confirm nominees.
- White House pulls FDA nominee amid political pushback The Washington Post
- White House Withdraws Nomination of Heidi Overton to Be F.D.A. Commissioner The New York Times
- White House pulls nomination of Heidi Overton to lead Food and Drug Administration – as it happened The Guardian
- Exclusive / Trump administration weighs Marshall for FDA as Overton wobbles Semafor
- White House Abandons Trump’s Pick to Lead the FDA WSJ
Want the full story? Read the original reporting
Read on The Washington Post